U.S. Consumer Durables Stock News

NasdaqGS:MIST
NasdaqGS:MISTPharmaceuticals

Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed?

Milestone Pharmaceuticals recently received U.S. Food and Drug Administration approval for CARDAMYST (etripamil) nasal spray, its first commercial product for at-home conversion of acute symptomatic paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults, with retail availability targeted for early 2026. This is the first new FDA-approved PSVT treatment in over 30 years and introduces a self-administered, out-of-hospital option for more than two million affected Americans,...
NasdaqGM:VERI
NasdaqGM:VERISoftware

Can Veritone’s (VERI) New Public-Sector AI Deals Deepen Its Justice and Safety Moat?

In early December 2025, Veritone, Inc. announced new public-sector collaborations and deployments, including integrating its iDEMS suite into Strategic Communications’ JPS TRUST program and partnering with Armada to deliver an edge-to-enterprise AI data fabric running on private AWS and Azure environments. These moves deepen Veritone’s role in AI-driven digital evidence and unstructured data management, potentially widening its reach across justice, public safety, federal, and commercial...
NYSE:REX
NYSE:REXOil and Gas

REX American Resources (REX): Reassessing Valuation After Stable Q3 Results and Softer Year-to-Date Profits

REX American Resources (REX) just posted its third quarter numbers, showing sales essentially flat year over year while earnings per share inched higher, even as year to date net income drifted lower. See our latest analysis for REX American Resources. That steadiness in the latest earnings comes after a strong run, with the share price up about 55% year to date and a 1 year total shareholder return of nearly 61%. This suggests positive momentum despite recent profit pressure. If REX's move...
NasdaqGS:PGEN
NasdaqGS:PGENBiotechs

US High Growth Tech Stocks To Watch December 2025

As the United States market navigates a period of volatility, with major indexes closing lower amid concerns over an AI bubble and looming economic reports, investors are keenly observing the tech sector's dynamics. In such a climate, identifying high-growth tech stocks involves looking for companies with strong fundamentals and resilience to market pressures.
NasdaqGS:NTNX
NasdaqGS:NTNXSoftware

3 Stocks Estimated To Be Trading At Discounts Of 23.8% To 35.3%

As the United States stock market grapples with concerns over an AI bubble and fluctuating major indexes, investors are keenly observing economic indicators like the upcoming jobs report to gauge future market directions. In this environment of uncertainty, identifying stocks that are potentially undervalued can offer opportunities for those looking to capitalize on price discrepancies; such stocks may be trading at significant discounts relative to their intrinsic value, providing a...
NasdaqCM:PAYS
NasdaqCM:PAYSDiversified Financial

Three Insider-Favored Growth Companies To Watch

As the U.S. stock market grapples with pressures on AI stocks and anticipates key economic data releases, investors are keenly observing how these factors influence broader market trends. In such a volatile environment, growth companies with high insider ownership often stand out as they suggest confidence from those closest to the business, making them intriguing prospects for investors seeking stability amid uncertainty.
NasdaqGM:ARTV
NasdaqGM:ARTVBiotechs

Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders

As the year draws to a close, U.S. markets are experiencing volatility, with major indexes closing lower amid concerns about an AI bubble and looming economic reports. In such a climate, investors often look beyond the large-cap stocks dominating headlines to explore opportunities in lesser-known areas like penny stocks. While the term "penny stocks" may seem outdated, it continues to signify smaller or emerging companies that could offer significant value when backed by strong financials and...
NYSE:DOC
NYSE:DOCHealth Care REITs

Is Healthpeak Properties Now a Value Opportunity After a Tough 2025 Share Price Slide?

Wondering if Healthpeak Properties is starting to look like a bargain after a tough run, or if the market sees trouble that is not obvious yet? Let us walk through what the numbers are really saying about its value. The stock is trading around $16.36, with returns of about -0.8% over the last week, -5.7% over the last month, and a much steeper -18.8% year to date, which has clearly tested investors' patience. Recently, the stock has been in focus as investors reassess listed healthcare REITs...